Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07522073 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 3 study, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 588
- Enrollment target
NCT07522073 is a Phase 3 study that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 588 participants.
The verdict
NCT07522073, a Phase 3 study, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 588 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Interventions
- DRUG Placebo
- DRUG INCB161734
- DRUG Investigator's choice of chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 588 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2029-03-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07522073
The ClinicalTrials.gov registry entry for NCT07522073 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 588 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07522073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07522073 about?
NCT07522073 is a clinical study titled "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT07522073?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 588 participants. The study started on 2026-04-09. Estimated completion is 2029-03-19.
What interventions are being tested in trial NCT07522073?
The interventions under investigation include: Placebo (DRUG), INCB161734 (DRUG), Investigator's choice of chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07522073?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.